Gergely Tóth

Chief Executive Officer at Cantabio Pharmaceuticals Inc

Location:
1250 Oakmead Pkwy, Sunnyvale, California, United States
Company:
Cantabio Pharmaceuticals Inc
HQ Phone:
(844) 200-2826
Wrong Gergely Tóth?

Last Updated 10/13/2017

General Information

Employment History

Web Partner  - Barnett International

Education

Executive MBA  - Judge Business School at the University of Cambridge ( UK )

Ph.D.  - Department of Biomedical Sciences

Ph.D.  - Purdue University

Ph.D.  - University of Cambridge , UK

Ph.D.  - Germanic linguistics , UC-Berkeley

Affiliations

Founder  - Gardedam Therapeutics

Post-Doctoral Fellow At the Department of Molecular Biology  - Berkeley

Post-Doctoral Fellow At the Department of Molecular Biology  - Berkeley

Program Advisor  - Cambridge Healthtech Institute

Scientific Advisory Board Member  - European Peptide Society

Secretary  - San Francisco Bay Area Hungarian Heritage Foundation

Web References  

Management Team :: Cantabio Pharmaceuticals Inc. (CTBO)

Gergely Tóth, Ph.D., M.B.A.
Gergely Tóth, Ph.D., M.B.A. Founder, Chief Executive Officer Dr Gergely Tóth founded Gardedam Therapeutics in Palo Alto, CA in 2009 and is CEO of Cantabio Pharmaceuticals. Dr. Tóth is also affiliated with the Wolfson Brain Imaging Centre at University of Cambridge (UK) and with the Research Center for Natural Sciences at the Hungarian Academy of Sciences (Hungary) as the Head of the Research Group for Neurodegenerative Disease Drug Discovery. He is a scientist and a serial entrepreneur with a long-term focus on developing therapeutics for neurodegenerative diseases. He holds a Ph.D. from the Department of Biomedical Sciences at Creighton University (U.S.) in 2001, and an Executive M.B.A. in 2012 from the Judge Business School at the University of Cambridge (UK). He was a post-doctoral fellow at the Department of Molecular Biology at the University of California at Berkeley (U.S.). Dr. Tóth previously held various research roles in small and global biopharmaceutical companies in the U.S., where he mostly pursued drug discovery research for Parkinson's disease and Alzheimer's disease.

Read More
Board of Directors :: Cantabio Pharmaceuticals Inc. (CTBO)

Gergely Tóth, Ph.D., M.B.A.
Founder, Chief Executive Officer Dr Gergely Tóth founded Gardedam Therapeutics in Palo Alto, CA in 2009 and is CEO of Cantabio Pharmaceuticals. Dr. Tóth is also affiliated with the Wolfson Brain Imaging Centre at University of Cambridge (UK) and with the Research Center for Natural Sciences at the Hungarian Academy of Sciences (Hungary) as the Head of the Research Group for Neurodegenerative Disease Drug Discovery. He is a scientist and a serial entrepreneur with a long-term focus on developing therapeutics for neurodegenerative diseases. He holds a Ph.D. from the Department of Biomedical Sciences at Creighton University (U.S.) in 2001, and an Executive M.B.A. in 2012 from the Judge Business School at the University of Cambridge (UK). He was a post-doctoral fellow at the Department of Molecular Biology at the University of California at Berkeley (U.S.). Dr. Tóth previously held various research roles in small and global biopharmaceutical companies in the U.S., where he mostly pursued drug discovery research for Parkinson's disease and Alzheimer's disease.

Read More
Management Team :: Cantabio Pharmaceuticals Inc. (CTBO)

Gergely Tóth, Ph.D., M.B.A.
Gergely Tóth, Ph.D., M.B.A. Founder, Chief Executive Officer Dr Gergely Tóth founded Gardedam Therapeutics in Palo Alto, CA in 2009 and is CEO of Cantabio Pharmaceuticals. Dr. Tóth is also affiliated with the Wolfson Brain Imaging Centre at University of Cambridge (UK) and with the Research Center for Natural Sciences at the Hungarian Academy of Sciences (Hungary) as the Head of the Research Group for Neurodegenerative Disease Drug Discovery. He is a scientist and a serial entrepreneur with a long-term focus on developing therapeutics for neurodegenerative diseases. He holds a Ph.D. from the Department of Biomedical Sciences at Creighton University (U.S.) in 2001, and an Executive M.B.A. in 2012 from the Judge Business School at the University of Cambridge (UK). He was a post-doctoral fellow at the Department of Molecular Biology at the University of California at Berkeley (U.S.). Dr. Tóth previously held various research roles in small and global biopharmaceutical companies in the U.S., where he mostly pursued drug discovery research for Parkinson's disease and Alzheimer's disease.

Read More

Browse ZoomInfo’s Directories